As far as OX40 agonists are concerned, they have been shown to enhance proliferation in conventional CD4 and CD8 T cells,19 and perhaps the proliferation and activity of the non-Treg after anti-OX40 administration overcomes Treg inhibition, leading to tumor destruction. Here, CD8A is linked to neoplasm.